Certara Inc is a leading provider of software and services that streamline the drug development process, helping biopharmaceutical companies bring new therapies to market more efficiently
The company specializes in optimizing preclinical and clinical development through advanced modeling and simulation, as well as utilizing innovative technologies to enhance decision-making in drug discovery and development. By leveraging their proprietary software platforms and extensive expertise, Certara supports clients in process optimization, regulatory compliance, and data analysis, ultimately contributing to improved patient outcomes and accelerated access to new medications.
Gainers Lipella Pharmaceuticals Inc. (NASDAQLIPO) shares jumped 40.2% to $2.5109 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis.
